ArticleJournal of fluorescence2025
pH-triggered Fluorescent-Active Antifouling Microgels Having Disulfide Crosslinked Core for the Application of Site-Specific REDOX-Active Drug Delivery to the Triple Negative Cancer Cells MDA-MB-231.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This work reports the tailor-made functional microgels for the anticancer drug doxorubicin’s (DOX) delivery to cancer cells. Disulfide crosslinked microgels were synthesized through water in oil (w/o) mini-emulsion polymerization, followed by surface functionalization with rhodamine amine (RhNH2, fluorescent active agent) and polysulfobetaine (zwitterion) brushes, respectively. Here, RhNH2 responded to the microgel’s pH alteration by appearing in the emission range of fluorescence at 565–585 nm, and the occurrence of polysulfobetaine lessened model protein adsorption, which is here bovine serum albumin (BSA) (~ 20% reduction). This multifaceted microgel was categorized using different characterizations. Synthesized microgels showed a % drug loading content (%DLC) of (8 ± 2)% as well as a % drug loading efficiency (%DLE) of (80 ± 5)%. The cytotoxic behavior of biopolymer-based microgel was computed over MDA-MB-231 (IC50 125 µg/mL) cancer cells through MTT assay, remarking that the designed microgel is non-toxic, although drug-loaded microgels exhibited consequential toxicity. To comprehend cell apoptosis along with the cancer cells’ response to drug-loaded microgels, FACS, and cell uptake (in vitro) investigations were performed. These fluorescent active, non-toxic, zwitterionic, and REDOX-responsive microgels could be a potential candidate for promoting a significant inhibitory impact on cancer cells.
Indexed as
Identifiers
40512373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.